Shingrix Drug Interactions

Shingrix can be given concomitantly with unadjuvanted inactivated seasonal influenza vaccine, 23-valent pneumococcal polysaccharide vaccine (PPV23) or reduced antigen diphtheria-tetanus-acellular pertussis vaccine (dTpa). The vaccines should be administered at different injection sites.
In three phase III, controlled, open-label clinical studies, adults ≥50 years of age were randomised to receive 2 doses of Shingrix 2 months apart administered either concomitantly at the first dose or non-concomitantly with an unadjuvanted inactivated seasonal influenza vaccine (N=828; Zoster-004), a PPV23 vaccine (N=865; Zoster-035) or a dTpa vaccine formulated with 0.3 milligrams Al³⁺ (N=830; Zoster-042). The immune responses of the co-administered vaccines were unaffected, with the exception of lower geometric mean concentrations (GMCs) for one of the pertussis antigens (pertactin) when Shingrix is co-administered with the dTpa vaccine. The clinical relevance of this data is not known.
The adverse reactions of fever and shivering were more frequent when PPV23 vaccine is co-administered with Shingrix.
Concomitant use with other vaccines is not recommended due to lack of data.